NCT07341867 2026-01-14Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeDana-Farber Cancer InstitutePhase 1 Not yet recruiting90 enrolled
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts